Participating Faculty

This supplement to The American Journal of Managed Care provides information on the burden of transient ischemic attack (TIA) and stroke and the consequences of its persistent underdiagnosis, to the way different governmental organizations and military healthcare providers address the treatment of TIA and stroke, and how they compare with private insurers and private hospitals.

Participating Faculty

Philip B. Gorelick, MD, MPH, FACP

John S. Garvin Professor and Head Director, Center for Stroke Research

Department of Neurology and Rehabilitation

University of Illinois College of Medicine at Chicago

Chicago, Illinois

Chad Kessler, MD, FAAEMSection Chief, Emergency Medicine

Jesse Brown VA Hospital

National Advisory Committee for VA Emergency Medicine

Assistant Professor, Departments of Internal Medicine, Emergency Medicine and Medical Education Associate Program Director, Combined Internal Medicine/Emergency Medicine Residency

University of Illinois-Chicago

Chicago, Illinois

Allan Jay Kogan, MD, MSS, ABFP, FAAFP, CPE

Department of Medical Management

Cigna-Great West Healthcare

Dallas, Texas

Steven N. Singh, MDProfessor of Medicine and Pharmacology

Georgetown University Medical Center

Chief of Cardiology

Department of Medicine

Veteran Affairs Medical Center

Washington, DC

Kurian E. Thomas, MD

Clinical Instructor

Department of Neurology

Jesse Brown Veterans Administration Medical Center

Chicago, Illinois

Faculty Disclosures

Philip B. Gorelick, MD, MPH, FACPConsultant/Advisory board:Bayer

Boehringer Ingelheim

Bristol-Myers Squibb/Sanofi

Pfizer

Lecturer:Boehringer Ingelheim

Chad Kessler, MD, FAAEM, Allan Jay Kogan, MD, MSS, ABFP, FAAFP, CPE, Steven N. Singh, MD, and Kurian E. Thomas, MD, report no financial interest/relationship relating to the topic of this activity.

Editorial support for this supplement was provided by Clinical Care Targeted Communications with financial support provided by Boehringer Ingelheim.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Download PDF: Participating Faculty